1 |
Mavroudi M, Zarogoulidis P, Katsikogiannis N, et al. Lymphangioleiomyomatosis:current and future[J]. J Thorac Dis, 2013, 5(1): 74-79.
|
2 |
Krymskaya VP. Treatment Option(s) for Pulmonary Lymphangioleiomyomatosis Progress and Current Challenges[J]. Am J Respir Cell Mol Biol, 2012, 46(5): 563-565.
|
3 |
Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis[J]. Proc Natl Acad Sci USA, 2000, 97(11): 6085-6090.
|
4 |
Hecimovic A, Jakopovic M, Pavlisa G, et al. Successful treatment of pulmonary and lymphatic manifestations of lymphangioleiomyomatosis with sirolimus[J]. Lymphology, 2015, 48(2): 97-102.
|
5 |
Taveira-DaSilva AM, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis[J]. Clin Epidemiol, 2015, 7: 249-257.
|
6 |
Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases[J]. Chest, 2010, 138(3): 674-681.
|
7 |
王涛. 肺淋巴管平滑肌瘤病的X线、CT表现[J]. 当代医学,2011, 17(33): 11-12.
|
8 |
张龙举,梁毅,钟小宁,等. 国内三十余年肺淋巴管肌瘤病130例临床与病理文献复习分析[J]. 中国全科医学,2015, 18(3): 329-334.
|
9 |
Fujita A, Ando K, Kobayashi E, et al. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing[J]. Hum Genet, 2015, 135(1): 61-68.
|
10 |
Freitas CS, Baldi BG, Araujo MS, et al. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations[J]. J Bras Pneumol, 2015, 41(3): 275-280.
|